Site Search
Displaying results 171 - 180 of 573
Resource | Publications,
The report provides a comprehensive and up-to-date assessment of the TB epidemic, and of progress in prevention, diagnosis and treatment, at global, regional and country levels. This is done in the context of recommended global TB strategies and associated targets, as well as broader development goals set by the United Nations.
WHO has published a global TB report every year since 1997.
Resource | Guidelines,
Antiretroviral therapy using dolutegravir has several advantages over other regimens, including clinical superiority, improved side-effect profile, and reduced risk of viral resistance.
This is the first time this regimen will be offered as an affordable, generic, fixed-dose combination, which will increase access for millions of people living with HIV in low- and middle-income countries. Below are a set of key messages and questions and answers to guide communications around the announcement and respond to media inquiries.
Resource | Fact Sheets,
In this Region, most mothers and children receive health services during pregnancy, delivery and in the months after birth. However, when services for HIV, hepatitis B and syphilis are planned and delivered through separate, uncoordinated, vertical programmes in the health system, this can result in redundancies, missed opportunities, and an inefficient use of resources. It can also make it harder for women and babies to get these important services.
The shared maternal, newborn and child health platform can coordinate and integrate interventions to achieve efficiencies and cost-effectively prevent these infections to achieve elimination.
Resource | Guidelines,
In 2016, WHO published its consolidated guidelines on the use of antiretroviral (ARV) drugs for treating and preventing HIV infection. As part of this revision, WHO recognized that, as antiretroviral therapy (ART) is scaled up and countries adopt the “treat all” policy, ART services
will need to be differentiated to provide adapted packages of care to people living with HIV with varied clinical needs.
The objectives of these guidelines are to provide recommendations outlining a public health approach to managing people presenting with advanced HIV disease, and to provide guidance on the timing of initiation of antiretroviral therapy (ART) for all people living with HIV. To develop these recommendations, WHO convened a Guideline Development Group in March 2017. Using the evidence generated through two systematic reviews, the GRADE process was used to determine the strength of the recommendation and quality of the evidence.
Resource | Fact Sheets,
Background about ART program in Nepal:
- ART service started from February 2004 from Sukraraj Tropical and infectious Disease Hospital, Kathmandu in Nepal.
- ART is available for free of cost for People Living with HIV (PLHIV).
- As of July 2017, there are 68 ART sites and 25 ART Dispensing Centers (ADCs) throughout the country.
- ADCs are established to increase accessibility to the treatment.
- Nepal has also adopted Test and Treat approach since Feb 2017.
- National Consolidated Guideline for Treating and Preventing HIV in Nepal 2014 and revised in 2017 is the guiding document for providing HIV treatment and care in Nepal.
- CD4 count service is available from 30 sites and across the country.
- Viral load testing service is available from National Public Health Laboratory
Resource | Fact Sheets,
HIV data on prevention mother-to-child transmission (PMTCT) and early infant diagnosis (EID) in Nepal.
Resource | Publications,
Preventing and managing the emergence of HIV Drug Resistance (HIVDR) is a key component of a comprehensive and effective HIV response, and should be integrated into broader efforts to ensure sustainability and greatest impact. It is essential that actions to monitor, prevent and respond to HIVDR are implemented at the clinical, programme and policy levels to address the many drivers of HIVDR.
The goal of this Global Action Plan is to articulate synergistic actions that will be required to prevent HIVDR from undermining efforts to achieve global targets on health and HIV, and to provide the most effective treatment to all people living with HIV including adults, key populations, pregnant and breastfeeding women, children and adolescents.
Resource | Publications,
It is estimated that by the end of 2016, nearly 37 million people were living with HIV, of whom 19.5 million were taking life-saving antiretroviral therapy (ART). This number highlights the incredible progress made in expanding access to treatment, but also underscores the effort still required to fully implement the World Health Organization’s (WHO) “treat all” recommendation.
Adoption of the United Nations’ 2030 Agenda for Sustainable Development and WHO’s Global health sector strategy on HIV, 2016–2021 demonstrate the commitment of countries to end the AIDS epidemic by 2030. To track progress towards this goal, WHO and the Joint United Nations Programme on HIV/AIDS (UNAIDS) have set the target of 90% of people living with HIV on ART to achieve virological suppression by 2020, rising to 95% by 2030.
Resource | Publications,
Monitoring of individuals on Antiretroviral therapy (ART) is important to ensure treatment efficacy and improved health outcomes.
Resource | Publications,
As of June 2017, more than 20 low- and middle-income countries have included or are planning to include dolutegravir (DTG) as a first-line option in their national guidelines. This technical update summarizes the recent evidence and provides programme considerations to support countries on how to transition to new antiretroviral (ARV) drugs for use in first- and second-line ARV in low and middle- income countries.